North Estonia Medical Centre Foundation

The North Estonia Medical Centre Foundation’s nephrology unit is testing innovative treatments to reduce proteinuria and protect renal function in patients with immunoglobulin A nephropathy and other glomerular disorders.

• Immunoglobulin A nephropathy
• Focal segmental glomerulosclerosis
• Chronic kidney disease
• End‑stage kidney disease on dialysis
• Proteinuria reduction strategies

These studies aim to improve long‑term outcomes for individuals with chronic kidney disease and those receiving dialysis.

Researchers are evaluating new immunotherapies and targeted agents to extend survival in a range of malignancies, including non‑small cell lung cancer and hematologic cancers.

• Non‑small cell lung cancer
• Gastric and gastroesophageal adenocarcinoma
• Metastatic castration‑resistant prostate cancer
• Acute myeloid leukemia
• Multiple myeloma
• Colorectal cancer

The goal is to assess the efficacy of novel drug combinations and improve disease‑free survival across solid tumors and blood cancers.

The centre is conducting trials that explore innovative anticoagulants and lipid‑lowering therapies to lower the risk of major cardiovascular events in high‑risk populations, such as those with atrial fibrillation or elevated genetic risk.

• Atherosclerotic cardiovascular disease
• Atrial fibrillation
• Hypercholesterolemia
• High polygenic risk for coronary artery disease
• LDL‑cholesterol reduction

These investigations seek to demonstrate reductions in heart attacks, strokes, and cardiovascular mortality.

Ongoing studies focus on biologic and small‑molecule agents designed to control inflammation in conditions such as psoriatic arthritis and inflammatory bowel disease.

• Psoriatic arthritis
• Rheumatoid arthritis
• Moderate to severe ulcerative colitis
• Crohn's disease
• Plaque psoriasis

The purpose of these trials is to achieve better symptom control, reduce disease flares, and improve patients’ quality of life.

The site is evaluating new antimicrobial and antifibrotic compounds to treat serious infections and progressive lung diseases, including complicated urinary tract infections and fibrotic interstitial lung disorders.

• Complicated urinary tract infection
• Chronic obstructive pulmonary disease
• Idiopathic pulmonary fibrosis
• Progressive fibrosing interstitial lung disease
• Pulmonary emphysema due to Alpha‑1 antitrypsin deficiency

These trials aim to improve infection cure rates and slow lung function decline in affected patients.